Back to top
more

Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

(Delayed Data from NYSE)

$83.15 USD

83.15
433,581

-2.60 (-3.03%)

Updated Feb 25, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (199 out of 253)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Why Biohaven (BHVN) Might Surprise This Earnings Season

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans

Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.

Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data

Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.

Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).

Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study

Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.

Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate

Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.

Are Options Traders Betting on a Big Move in Biohaven (BHVN) Stock?

Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.

Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

Why Earnings Season Could Be Great for Biohaven (BHVN)

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Cigna (CI) Maintain Its Beat Streak in Q3 Earnings?

Cigna's (CI) Q3 results are likely to reflect revenue growth owing to a strong fundamental performance. Earnings, however, might have been affected by steep medical costs from moderation in deferment of care related to the COVID-19 pandemic.

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

FDA Accepts Biohaven's (BHVN) sNDA for Migraine Drug Nurtec

Biohaven (BHVN) is seeking the label expansion of its migraine drug Nurtec ODT as a preventive treatment of migraine.

Biohaven (BHVN) Q2 Earnings Beat on Strong Nurtec Uptake

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, demonstrates strong launch uptake.

Why Biohaven (BHVN) Might Surprise This Earnings Season

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More

The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.

Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock

Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Biohaven (BHVN) Stock

Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock

Biohaven Pharmaceutical (BHVN) needs investors to pay close attention to the stock based on moves in the options market lately.

Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options

Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.

What Makes Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a Strong Momentum Stock: Buy Now?

Does Biohaven Pharmaceutical Holding Company Ltd. (BHVN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are Options Traders Betting on a Big Move in Biohaven (BHVN) Stock?

Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.

Madeleine Johnson headshot

Bull of the Day: Illumina (ILMN)

Invest in the medical space with this DNA sequencing-focused company.

Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options

Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.

New Strong Sell Stocks for June 12th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Express Scripts (ESRX) to Launch Pilot Program, Shares Up

Express Scripts (ESRX) aims to add value to patients' diagnosis in return for higher costs.